186 related articles for article (PubMed ID: 35365405)
1. Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder.
Pals H; Bratberg J
J Am Pharm Assoc (2003); 2022; 62(4):1422-1429. PubMed ID: 35365405
[TBL] [Abstract][Full Text] [Related]
2. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
3. Care Practices of Mental Health Clinical Pharmacist Practitioners Within an Interdisciplinary Primary Care Model for Patients With Substance Use Disorders.
Percy A; Kelley AT; Valentino N; Butz A; Baylis JD; Suo Y; Gordon AJ; Jones AL
Subst Abus; 2023 Oct; 44(4):330-336. PubMed ID: 37840212
[TBL] [Abstract][Full Text] [Related]
4. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
5. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
[TBL] [Abstract][Full Text] [Related]
7. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
8. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
Speight C; Caiola C; Tyndall DE; Scott ES
J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
[TBL] [Abstract][Full Text] [Related]
9. Treatment access for opioid use disorder in pregnancy among rural and American Indian communities.
Kelley AT; Smid MC; Baylis JD; Charron E; Begaye LJ; Binns-Calvey A; Archer S; Weiner S; Pettey W; Cochran G
J Subst Abuse Treat; 2022 May; 136():108685. PubMed ID: 34953636
[TBL] [Abstract][Full Text] [Related]
10. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
[TBL] [Abstract][Full Text] [Related]
11. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
DiPaula BA; Menachery E
J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
[TBL] [Abstract][Full Text] [Related]
12. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
13. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
14. Collaborative approach to harm reduction by managed care pharmacy team for populations with substance use disorder.
Osibanjo O; Reinhardt R; Clemans S; Andoniadis S; Carson P; Benkstein K
J Am Pharm Assoc (2003); 2023; 63(1):396-402. PubMed ID: 36564331
[TBL] [Abstract][Full Text] [Related]
15. Collaborative care in the treatment of opioid use disorder and mental health conditions in primary care: A clinical study protocol.
Harris RA; Mandell DS; Kampman KM; Bao Y; Campbell K; Cidav Z; Coviello DM; French R; Livesey C; Lowenstein M; Lynch KG; McKay JR; Oslin DW; Wolk CB; Bogner HR
Contemp Clin Trials; 2021 Apr; 103():106325. PubMed ID: 33631356
[TBL] [Abstract][Full Text] [Related]
16. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
17. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
18. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
19. Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study.
Raman SR; Ford CB; Hammill BG; Clark AG; Clifton DC; Jackson GL
Addict Sci Clin Pract; 2023 Jul; 18(1):42. PubMed ID: 37434260
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
